tirzepatide in nash the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary Tirzepatide achieves high NASH resolution

What other dietary changes would you recommend

Frame the request around healthcare outcomes and long-term cost avoidance, not "weight loss coverage." The cardiovascular pathway: If you have established cardiovascular disease (previous heart attack, stroke, or peripheral arterial disease), Wegovy's CV indication may fall outside the weight loss exclusion entirely

Use the formula: is your target dose in mg, is the BAC water volume you reconstitute with in mL, and is the anchor compound mass in the vial in mg

For example, significant clinical trials such as the LEADER trial for Victoza and the SUSTAIN-6 trial for Ozempic have shown that these medications not only reduce the risk of major cardiovascular events but may also decrease the risk of cardiovascular-related death in this population